Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

247 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Telomere length and telomerase complex mutations in pediatric acute myeloid leukemia.
Aalbers AM, Calado RT, Young NS, Zwaan CM, Wu C, Kajigaya S, Coenen EA, Baruchel A, Geleijns K, de Haas V, Kaspers GJ, Kuijpers TW, Reinhardt D, Trka J, Zimmermann M, Pieters R, van der Velden VH, van den Heuvel-Eibrink MM. Aalbers AM, et al. Among authors: van der velden vh, van den heuvel eibrink mm. Leukemia. 2013 Aug;27(8):1786-9. doi: 10.1038/leu.2013.57. Epub 2013 Feb 21. Leukemia. 2013. PMID: 23426163 Free PMC article. No abstract available.
Is there a relationship between in vitro drug resistance and level of minimal residual disease as detected by polymerase chain reaction at the end of induction therapy in childhood acute lymphoblastic leukaemia?
De Haas V, Kaspers GJ, Oosten L, Bresters D, Pieters R, Van Der Velden VH, Van Wering ER, Van Den Berg H, Van Der Schoot CE. De Haas V, et al. Among authors: van der velden vh, van den berg h, van der schoot ce, van wering er. Br J Haematol. 2002 Sep;118(4):1190-1. doi: 10.1046/j.1365-2141.2002.36211.x. Br J Haematol. 2002. PMID: 12199807 Free article. No abstract available.
Immunobiological diversity in infant acute lymphoblastic leukemia is related to the occurrence and type of MLL gene rearrangement.
Jansen MW, Corral L, van der Velden VH, Panzer-Grümayer R, Schrappe M, Schrauder A, Marschalek R, Meyer C, den Boer ML, Hop WJ, Valsecchi MG, Basso G, Biondi A, Pieters R, van Dongen JJ. Jansen MW, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2007 Apr;21(4):633-41. doi: 10.1038/sj.leu.2404578. Epub 2007 Feb 1. Leukemia. 2007. PMID: 17268512
Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data.
van der Velden VH, Cazzaniga G, Schrauder A, Hancock J, Bader P, Panzer-Grumayer ER, Flohr T, Sutton R, Cave H, Madsen HO, Cayuela JM, Trka J, Eckert C, Foroni L, Zur Stadt U, Beldjord K, Raff T, van der Schoot CE, van Dongen JJ; European Study Group on MRD detection in ALL (ESG-MRD-ALL). van der Velden VH, et al. Among authors: van dongen jj, van der schoot ce. Leukemia. 2007 Apr;21(4):604-11. doi: 10.1038/sj.leu.2404586. Epub 2007 Feb 8. Leukemia. 2007. PMID: 17287850
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia.
Flohr T, Schrauder A, Cazzaniga G, Panzer-Grümayer R, van der Velden V, Fischer S, Stanulla M, Basso G, Niggli FK, Schäfer BW, Sutton R, Koehler R, Zimmermann M, Valsecchi MG, Gadner H, Masera G, Schrappe M, van Dongen JJ, Biondi A, Bartram CR; International BFM Study Group (I-BFM-SG). Flohr T, et al. Leukemia. 2008 Apr;22(4):771-82. doi: 10.1038/leu.2008.5. Epub 2008 Jan 31. Leukemia. 2008. PMID: 18239620 Clinical Trial.
Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
Van der Velden VH, Corral L, Valsecchi MG, Jansen MW, De Lorenzo P, Cazzaniga G, Panzer-Grümayer ER, Schrappe M, Schrauder A, Meyer C, Marschalek R, Nigro LL, Metzler M, Basso G, Mann G, Den Boer ML, Biondi A, Pieters R, Van Dongen JJ; Interfant-99 Study Group. Van der Velden VH, et al. Among authors: van dongen jj. Leukemia. 2009 Jun;23(6):1073-9. doi: 10.1038/leu.2009.17. Epub 2009 Feb 12. Leukemia. 2009. PMID: 19212338 Clinical Trial.
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study.
Willasch AM, Gruhn B, Coliva T, Kalinova M, Schneider G, Kreyenberg H, Steinbach D, Weber G, Hollink IH, Zwaan CM, Biondi A, van der Velden VH, Reinhardt D, Cazzaniga G, Bader P, Trka J; European Study Group on WT1 Expression in Childhood AML. Willasch AM, et al. Among authors: van der velden vh. Leukemia. 2009 Aug;23(8):1472-9. doi: 10.1038/leu.2009.51. Epub 2009 Mar 26. Leukemia. 2009. PMID: 19322206
Bimodal distribution of genomic MLL breakpoints in infant acute lymphoblastic leukemia treatment.
Jung R, Jacobs U, Krumbholz M, Langer T, Keller T, De Lorenzo P, Valsecchi MG, van der Velden VH, Moericke A, Stanulla M, Teigler-Schlegel A, Panzer-Gruemayer ER, van Dongen JJ, Schrappe M, den Boer ML, Pieters R, Rascher W, Metzler M. Jung R, et al. Among authors: van der velden vh, van dongen jj. Leukemia. 2010 Apr;24(4):903-7. doi: 10.1038/leu.2010.14. Epub 2010 Feb 18. Leukemia. 2010. PMID: 20164851 No abstract available.
Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97/MRC AML12 protocol.
van der Velden VH, van der Sluijs-Geling A, Gibson BE, te Marvelde JG, Hoogeveen PG, Hop WC, Wheatley K, Bierings MB, Schuurhuis GJ, de Graaf SS, van Wering ER, van Dongen JJ. van der Velden VH, et al. Among authors: van dongen jj, van wering er, van der sluijs geling a. Leukemia. 2010 Sep;24(9):1599-606. doi: 10.1038/leu.2010.153. Epub 2010 Jul 29. Leukemia. 2010. PMID: 20668473
247 results